352 related articles for article (PubMed ID: 15145111)
1. Hydroquinidine therapy in Brugada syndrome.
Hermida JS; Denjoy I; Clerc J; Extramiana F; Jarry G; Milliez P; Guicheney P; Di Fusco S; Rey JL; Cauchemez B; Leenhardt A
J Am Coll Cardiol; 2004 May; 43(10):1853-60. PubMed ID: 15145111
[TBL] [Abstract][Full Text] [Related]
2. Long-term follow-up of asymptomatic Brugada patients with inducible ventricular fibrillation under hydroquinidine.
Bouzeman A; Traulle S; Messali A; Extramiana F; Denjoy I; Narayanan K; Marijon E; Hermida JS; Leenhardt A
Europace; 2014 Apr; 16(4):572-7. PubMed ID: 24068450
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of quinidine in high-risk patients with Brugada syndrome.
Belhassen B; Glick A; Viskin S
Circulation; 2004 Sep; 110(13):1731-7. PubMed ID: 15381640
[TBL] [Abstract][Full Text] [Related]
4. Outcome after implantation of cardioverter defibrillator [corrected] in patients with Brugada syndrome: a multicenter Israeli study (ISRABRU).
Rosso R; Glick A; Glikson M; Wagshal A; Swissa M; Rosenhek S; Shetboun I; Khalamizer V; Fuchs T; Boulos M; Geist M; Strasberg B; Ilan M; Belhassen B;
Isr Med Assoc J; 2008 Jun; 10(6):435-9. PubMed ID: 18669142
[TBL] [Abstract][Full Text] [Related]
5. Excellent long-term reproducibility of the electrophysiologic efficacy of quinidine in patients with idiopathic ventricular fibrillation and Brugada syndrome.
Belhassen B; Glick A; Viskin S
Pacing Clin Electrophysiol; 2009 Mar; 32(3):294-301. PubMed ID: 19272057
[TBL] [Abstract][Full Text] [Related]
6. Predictive value of ventricular arrhythmia inducibility for subsequent ventricular tachycardia or ventricular fibrillation in Multicenter Automatic Defibrillator Implantation Trial (MADIT) II patients.
Daubert JP; Zareba W; Hall WJ; Schuger C; Corsello A; Leon AR; Andrews ML; McNitt S; Huang DT; Moss AJ;
J Am Coll Cardiol; 2006 Jan; 47(1):98-107. PubMed ID: 16386671
[TBL] [Abstract][Full Text] [Related]
7. Short QT syndrome: pharmacological treatment.
Gaita F; Giustetto C; Bianchi F; Schimpf R; Haissaguerre M; Calò L; Brugada R; Antzelevitch C; Borggrefe M; Wolpert C
J Am Coll Cardiol; 2004 Apr; 43(8):1494-9. PubMed ID: 15093889
[TBL] [Abstract][Full Text] [Related]
8. Induction of ventricular fibrillation rather than ventricular tachycardia predicts tachyarrhythmia recurrences in patients with idiopathic dilated cardiomyopathy and implantable cardioverter defibrillator for secondary prophylaxis.
Rolf S; Haverkamp W; Borggrefe M; Breithardt G; Bocker D
Europace; 2009 Mar; 11(3):289-96. PubMed ID: 19095687
[TBL] [Abstract][Full Text] [Related]
9. Inductionless or limited shock testing is possible in most patients with implantable cardioverter- defibrillators/cardiac resynchronization therapy defibrillators: results of the multicenter ASSURE Study (Arrhythmia Single Shock Defibrillation Threshold Testing Versus Upper Limit of Vulnerability: Risk Reduction Evaluation With Implantable Cardioverter-Defibrillator Implantations).
Day JD; Doshi RN; Belott P; Birgersdotter-Green U; Behboodikhah M; Ott P; Glatter KA; Tobias S; Frumin H; Lee BK; Merillat J; Wiener I; Wang S; Grogin H; Chun S; Patrawalla R; Crandall B; Osborn JS; Weiss JP; Lappe DL; Neuman S
Circulation; 2007 May; 115(18):2382-9. PubMed ID: 17470697
[TBL] [Abstract][Full Text] [Related]
10. Effects of low-dose quinidine on ventricular tachyarrhythmias in patients with Brugada syndrome: low-dose quinidine therapy as an adjunctive treatment.
Mizusawa Y; Sakurada H; Nishizaki M; Hiraoka M
J Cardiovasc Pharmacol; 2006 Mar; 47(3):359-64. PubMed ID: 16633076
[TBL] [Abstract][Full Text] [Related]
11. The QUIDAM study: Hydroquinidine therapy for the management of Brugada syndrome patients at high arrhythmic risk.
Andorin A; Gourraud JB; Mansourati J; Fouchard S; le Marec H; Maury P; Mabo P; Hermida JS; Deharo JC; Delasalle B; Esnault S; Sadoul N; Davy JM; Leenhardt A; Klug D; Defaye P; Babuty D; Sacher F; Probst V
Heart Rhythm; 2017 Aug; 14(8):1147-1154. PubMed ID: 28411139
[TBL] [Abstract][Full Text] [Related]
12. Arrhythmic storm responsive to quinidine in a patient with Brugada syndrome and vasovagal syncope.
Márquez MF; Rivera J; Hermosillo AG; Iturralde P; Colín L; Moragrega JL; Cárdenas M
Pacing Clin Electrophysiol; 2005 Aug; 28(8):870-3. PubMed ID: 16105018
[TBL] [Abstract][Full Text] [Related]
13. Prospective clinical evaluation and follow-up of a cohort of consecutive VT/VF patients, using a staged-care protocol, including coronary arteriography, programmed electrical stimulation and cardiac surgery.
Naccarella F; Rolli A; Carboni A; Finardi A; Aurier E; Favaro L; Contini S; Gherli T; Caponi D; Maranga SS; Lepera G; Bartoletti A
G Ital Cardiol; 1999 Oct; 29(10):1142-56. PubMed ID: 10546124
[TBL] [Abstract][Full Text] [Related]
14. Reduction in ventricular tachyarrhythmias with statins in the Multicenter Automatic Defibrillator Implantation Trial (MADIT)-II.
Vyas AK; Guo H; Moss AJ; Olshansky B; McNitt SA; Hall WJ; Zareba W; Steinberg JS; Fischer A; Ruskin J; Andrews ML;
J Am Coll Cardiol; 2006 Feb; 47(4):769-73. PubMed ID: 16487843
[TBL] [Abstract][Full Text] [Related]
15. Long-term follow-up of primary prophylactic implantable cardioverter-defibrillator therapy in Brugada syndrome.
Sarkozy A; Boussy T; Kourgiannides G; Chierchia GB; Richter S; De Potter T; Geelen P; Wellens F; Spreeuwenberg MD; Brugada P
Eur Heart J; 2007 Feb; 28(3):334-44. PubMed ID: 17251258
[TBL] [Abstract][Full Text] [Related]
16. Ventricular tachycardia in arrhythmogenic right ventricular dysplasia/cardiomyopathy: clinical presentation, risk stratification and results of long-term follow-up.
Pezawas T; Stix G; Kastner J; Schneider B; Wolzt M; Schmidinger H
Int J Cardiol; 2006 Mar; 107(3):360-8. PubMed ID: 16503259
[TBL] [Abstract][Full Text] [Related]
17. Predictors of VT/VF-occurrence in ICD patients: results from the PROFIT-Study.
Klein G; Lissel C; Fuchs AC; Gardiwal A; Oswald H; Desousa M; Pichlmaier AM; Lichtinghagen R; Geerlings H; Lippolt P; Niehaus M; Drexler H; Korte T
Europace; 2006 Aug; 8(8):618-24. PubMed ID: 16864615
[TBL] [Abstract][Full Text] [Related]
18. Ventricular arrhythmia following alcohol septal ablation for obstructive hypertrophic cardiomyopathy.
Noseworthy PA; Rosenberg MA; Fifer MA; Palacios IF; Lowry PA; Ruskin JN; Sanborn DM; Picard MH; Vlahakes GJ; Mela T; Das S
Am J Cardiol; 2009 Jul; 104(1):128-32. PubMed ID: 19576333
[TBL] [Abstract][Full Text] [Related]
19. Driving and implantable cardioverter-defibrillator shocks for ventricular arrhythmias: results from the TOVA study.
Albert CM; Rosenthal L; Calkins H; Steinberg JS; Ruskin JN; Wang P; Muller JE; Mittleman MA;
J Am Coll Cardiol; 2007 Dec; 50(23):2233-40. PubMed ID: 18061071
[TBL] [Abstract][Full Text] [Related]
20. Recurrent cardiac events in patients with idiopathic ventricular fibrillation, excluding patients with the Brugada syndrome.
Champagne J; Geelen P; Philippon F; Brugada P
BMC Med; 2005 Jan; 3():1. PubMed ID: 15627402
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
